210 related articles for article (PubMed ID: 19489184)
1. Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
Prescrire Int; 2008 Aug; 17(96):145. PubMed ID: 19489184
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
[No Abstract] [Full Text] [Related]
3. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
4. Managing complicated Crohn's disease in children and adolescents.
Homan M; Baldassano RN; Mamula P
Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
[TBL] [Abstract][Full Text] [Related]
5. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of infliximab in the course of treatment of Crohn's disease.
Bratcher JM; Korelitz BI
Expert Opin Drug Saf; 2006 Jan; 5(1):9-16. PubMed ID: 16370952
[TBL] [Abstract][Full Text] [Related]
7. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF antibody in Crohn's disease--status of information, comments and recommendations of an international working group.
Lochs H; Adler G; Beglinger C; Duchmann R; Emmrich J; Ewe K; Gangl A; Gasché C; Hahn E; Hoffmann P; Kaskas B; Malchow H; Pohl C; Raedler A; Renner E; Schölmerich J; Schreiber S; Stange E; Tilg H; Vogelsang H; Weigert N; Zeitz M
Z Gastroenterol; 1999 Jun; 37(6):509-12. PubMed ID: 10427657
[TBL] [Abstract][Full Text] [Related]
9. Infliximab (Remicade) for Crohn's disease.
Med Lett Drugs Ther; 1999 Feb; 41(1047):19-20. PubMed ID: 10076592
[No Abstract] [Full Text] [Related]
10. Biologic therapy in Crohn's disease.
Williams MD; Omran ML; Gordon GL
Mo Med; 2009; 106(5):356-60. PubMed ID: 19902717
[TBL] [Abstract][Full Text] [Related]
11. Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS; Huo D
Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
[No Abstract] [Full Text] [Related]
12. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.
Ahmad NM; Ahmad KM; Younus F
J Infect; 2007 Jan; 54(1):e29-32. PubMed ID: 16678268
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in Crohn's disease: a look at the (not so distant) future.
Sorrentino D; Terrosu G; Avellini C
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S229-35. PubMed ID: 18598994
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab: new indication. A last resort for treating plaque psoriasis: just another TNF alpha antagonist.
Prescrire Int; 2008 Dec; 17(98):240. PubMed ID: 19422152
[No Abstract] [Full Text] [Related]
15. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.
Herfarth H; Obermeier F; Andus T; Rogler G; Nikolaus S; Kuehbacher T; Schreiber S
Am J Gastroenterol; 2002 Oct; 97(10):2688-90. PubMed ID: 12385472
[No Abstract] [Full Text] [Related]
16. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
[TBL] [Abstract][Full Text] [Related]
17. Anorectal carcinoma after infliximab therapy in Crohn's disease: report of a case.
Melichar B; Bures J; Dedic K
Dis Colon Rectum; 2006 Aug; 49(8):1228-33. PubMed ID: 16845561
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in Crohn's disease: early and long-term treatment.
Armuzzi A; De Pascalis B; Fedeli P; De Vincentis F; Gasbarrini A
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S271-9. PubMed ID: 18599000
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials.
Rutgeerts P
Am J Gastroenterol; 2002 Oct; 97(10):2488-9. PubMed ID: 12385428
[No Abstract] [Full Text] [Related]
20. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M; Leonard MB; Hyams JS; Crandall WV; Kugathasan S; Otley AR; Olson A; Johanns J; Marano CW; Heuschkel RB; Veereman-Wauters G; Griffiths AM; Baldassano RN;
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1378-84. PubMed ID: 19081527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
